Search research articles
Contact Us
Filters
Showing results (1-10 of 125) with videos related to
Page
of 13
Sort By:
Current Pharmaceutical Design
|
August 20, 2009
Imaging the glutamate system in humans: relevance to drug discovery for schizophrenia
James M Stone
Therapeutic Advances in Psychopharmacology
|
August 29, 2013
Glutamatergic antipsychotic drugs: a new dawn in the treatment of schizophrenia?
James M Stone
Current Pharmaceutical Biotechnology
|
January 31, 2012
The glutamate hypothesis of schizophrenia: neuroimaging and drug development
Alice Egerton, James M Stone
European Psychiatry : the Journal of the Association of European Psychiatrists
|
March 21, 2006
The contribution of brain imaging to understanding the mechanism of second generation antipsychotic drugs
Lyn S Pilowsky, James M Stone
International Review of Psychiatry (Abingdon, England)
|
February 11, 2021
Ketamine for depression
Luke A Jelen, James M Stone
Expert Review of Neurotherapeutics
|
February 10, 2006
Antipsychotic drug action: targets for drug discovery with neurochemical imaging
James M Stone, Lyn S Pilowsky
The British Journal of Psychiatry : the Journal of Mental Science
|
June 11, 2019
When the drugs don't work: the potential of glutamatergic antipsychotics in schizophrenia - ADDENDUM
Evangelos Papanastasiou, James M Stone, Sukhi Shergill
The British Journal of Psychiatry : the Journal of Mental Science
|
February 5, 2013
When the drugs don't work: the potential of glutamatergic antipsychotics in schizophrenia
Evangelos Papanastasiou, James M Stone, Sukhi Shergill
Journal of Psychoactive Drugs
|
November 27, 2023
Association of Hallucinogen Persisting Perception Disorder with Trait Neuroticism and Mental Health Symptoms
Morgan Hadley, Alicia Halliday, James M Stone
Therapeutic Advances in Psychopharmacology
|
March 2, 2018
Alternatives to ketamine in depression: state-of-the-art and future perspectives
Luke A Jelen, Sinead King, James M Stone
Page
of 13
Search research articles
Search
Showing results (1-10 of 125) with videos related to
Sort By:
Page
of 13
Current Pharmaceutical Design
|
August 20, 2009
Imaging the glutamate system in humans: relevance to drug discovery for schizophrenia
James M Stone
Therapeutic Advances in Psychopharmacology
|
August 29, 2013
Glutamatergic antipsychotic drugs: a new dawn in the treatment of schizophrenia?
James M Stone
Current Pharmaceutical Biotechnology
|
January 31, 2012
The glutamate hypothesis of schizophrenia: neuroimaging and drug development
Alice Egerton, James M Stone
European Psychiatry : the Journal of the Association of European Psychiatrists
|
March 21, 2006
The contribution of brain imaging to understanding the mechanism of second generation antipsychotic drugs
Lyn S Pilowsky, James M Stone
International Review of Psychiatry (Abingdon, England)
|
February 11, 2021
Ketamine for depression
Luke A Jelen, James M Stone
Expert Review of Neurotherapeutics
|
February 10, 2006
Antipsychotic drug action: targets for drug discovery with neurochemical imaging
James M Stone, Lyn S Pilowsky
The British Journal of Psychiatry : the Journal of Mental Science
|
June 11, 2019
When the drugs don't work: the potential of glutamatergic antipsychotics in schizophrenia - ADDENDUM
Evangelos Papanastasiou, James M Stone, Sukhi Shergill
The British Journal of Psychiatry : the Journal of Mental Science
|
February 5, 2013
When the drugs don't work: the potential of glutamatergic antipsychotics in schizophrenia
Evangelos Papanastasiou, James M Stone, Sukhi Shergill
Journal of Psychoactive Drugs
|
November 27, 2023
Association of Hallucinogen Persisting Perception Disorder with Trait Neuroticism and Mental Health Symptoms
Morgan Hadley, Alicia Halliday, James M Stone
Therapeutic Advances in Psychopharmacology
|
March 2, 2018
Alternatives to ketamine in depression: state-of-the-art and future perspectives
Luke A Jelen, Sinead King, James M Stone
Page
of 13